Brief: Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis
29/05/2025 13:54
May 29 (Reuters) - Corestemchemon Inc 166480.KQ: NEURONATA-R® STEM CELL THERAPY SHOWS PROMISE IN ALS PHASE 3 SUBGROUP ANALYSIS, MOVES TOWARD FDA ACCELERATED APPROVAL Source text: ID:nPnTMNCja Further company coverage: 166480.KQ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corestemchemon
See all newsBrief: Corestemchemon To Divest 2.7 Billion Won Worth Of Own Shares
Brief: Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis
Brief: Corestemchemon To Divest 3.4 Billion Won Worth Of Own Shares
Brief: Corestemchemon To Divest 3.6 Billion Won Worth Of Own Shares
Brief: Corestemchemon To Divest 10.5 Billion Won Worth Of Own Shares